HOME- 자료실
- 최신 논문
SITE MAP
-
학회소개
-
학회소식
-
학술행사
-
분과전문의
-
자료실
-
학회지(JGO)
-
관련 사이트
총 게시글 : 196
-
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study 2026-06-24 VIEW : 6
-
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer 2026-06-24 VIEW : 6
-
Quality-adjusted progression-free survival analysis of veliparib and carboplatin/paclitaxel compared with chemotherapy alone in patients with newly diagnosed ovarian cancer (VELIA/GOG3005): ancillary analysis of a placebo-controlled, phase 3 randomized tr 2026-06-24 VIEW : 3
-
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial 2026-06-24 VIEW : 4
-
Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer 2026-06-24 VIEW : 2
-
Spatiotemporal Immune Determinants of Response to Immune Rechallenge in Advanced Cervical Cancer 2026-06-24 VIEW : 2
-
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial 2026-06-24 VIEW : 2
-
Phase II study of pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025) 2026-06-24 VIEW : 4
-
Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study 2026-06-24 VIEW : 3
-
Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial 2026-06-24 VIEW : 2
-
Endometrial cancer: A Society of Gynecologic Oncology evidence-based review and recommendations, part II 2026-06-24 VIEW : 5
-
Endometrial cancer: A Society of Gynecologic Oncology evidence-based review and recommendations: Part I 2026-06-24 VIEW : 7
-
Prognostic role of immunohistochemical and molecular markers in no specific molecular profile endometrial cancer: a systematic review and meta-analysis exploratory analyses of the DUO- E/GOG-3041/ENGOT-EN10 trial. 2026-06-24 VIEW : 5
-
Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial 2026-06-24 VIEW : 1
-
Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial 2026-06-24 VIEW : 3